Sun Pharmaceutical Industries of Mumbai, India has entered an agreement to acquire Ranbaxy Laboratories from parent company Daiichi Sankyo, in a transaction valued at $4 billion. The combined company will be India’s largest pharmaceutical company and the world’s fifth-largest generic company, with an estimated annual revenue of $4.2 billion. The acquisition is subject to shareholder approval from both companies.   In January, the FDA prohibited Ranbaxy from selling drugs in the U.S. ...